The historic rise of Viagra has long been a symbol of pharmaceutical success, but its position within the broader sector now triggers questions about potential returns . Copycat versions are undercutting exclusivity , causing concerns that supporting companies closely tied to Viagra's previous position could be a problematic strategy, especially gi